Using AI to Prevent Heart Disease
Artificial Intelligence for Preventing Heart Disease: Observational, Single Center, Prospective and Retrospective Study
This study is testing whether using artificial intelligence to look at heart scans can help doctors find patients with early signs of heart disease who might need more treatment to prevent serious heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milano) |
| Trial ID | NCT06029387 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with coronary artery disease (CAD) who have undergone coronary computed tomography angiography (cCTA). It aims to assess the risk of disease progression in patients with non-obstructive CAD by utilizing artificial intelligence to analyze atherosclerotic plaque characteristics. The goal is to identify patients who may benefit from more aggressive medical treatment to prevent major adverse cardiovascular events (MACEs). The study will integrate various prognostic imaging and clinical parameters to enhance predictive accuracy.
Who should consider this trial
Good fit: Ideal candidates are patients who have undergone cCTA for CAD assessment.
Not a fit: Patients under 18 years old or those with significant cardiovascular comorbidities will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management and outcomes for patients with non-obstructive CAD.
How similar studies have performed: While there have been various approaches to managing non-obstructive CAD, this study's integration of AI for risk assessment is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with cCTA performed for CAD assessment Exclusion Criteria: 1. Refusal to participate in the study 2. Age \<18 years old 3. Presence of other cardiovascular comorbidities (e.g. severe valvulopathies; non-ischemic cardiomyopathies; etc.)
Where this trial is running
Milano
- IRCCS San Raffaele — Milano, Italy (Recruiting)
Study contacts
- Principal investigator: Antonio Esposito — IRCCS San Raffaele
- Study coordinator: Antonio Esposito
- Email: esposito.antonio@hsr.it
- Phone: 02 2643 6102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.